Excellent Q3 results. Crossed Rs.5000 crores in quarterly sales for the first time, and EBITDA margin crossed 20% after a long time. Surprisingly, Europe’s contributed strongly and US only grew marginally (I thought US sales would be better).
With their recent launches and approvals, the company seems set for a few good quarters unless some FDA issue strikes again or some goodwill write-downs are still left (don’t think so, but they did make a few small acquisitions recently).
The stock’s of course already run up a fair bit. Theoretically, seems fairly valued now, but with the growth momentum and improving margins, can go up some more. If one of their recent and upcoming launches translate into higher sales than anticipated, then it can go up substantially too.
| Subscribe To Our Free Newsletter |
